Main Products/ Services/ Pipelines & Platforms
Our main product, CAL056: ▪ an orally administrated, anti-cancer drug, modulated proteasome pathway, with high selectivity of cytotoxicity and anti-proliferation activity toward cancer cells. ▪ CAL056 has shown tumor growth inhibition in various animal models including colorectal cancer, lung cancer, pancreatic cancer, breast cancer, bladder cancer, pancreatic cancer, multiple myeloma, and acute myeloid leukemia (AML). Besides, CAL056 also shown great potential in inflammation related disease such as lung fibrosis. ▪ Advantages: (1) With the high selectivity of cytotoxicity and anti-proliferation activity toward cancer cells, CAL056 expresses a broad therapeutic window which largely enhances the safety of treatment. (2) CAL056 shows relatively little side effects compared to other current commercial available products targeting ubiquitin proteasome pathway, such as Bortezomib. (3) As an oral anti-cancer drug, CAL056 owns a good oral bioavailability.
▪ CALGENT primarily focuses on the process from preclinical to clinical proof of concept (PoC) during the drug development value chain. CALGENT primarily targets highly novel projects with new molecular entities (NME) and niche technology platforms, in-licensing them from or partnering with academic institutions and biotech or pharma companies, both locally and internationally. Projects are selected based on their novelty as a drug target or platform technology for diseases where there are unmet medical needs. ▪ Upon reaching the clinical PoC, CALGENT will out-license or partner with the best-suited third party to continue development through market approvals and commercialization, maximizing profit through royalty, milestones, or profit sharing.